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Background:Dilute Russell Viper Venom Time (DRVV-T)might be useful in urgent settings for screening patients
on Non-VKA Oral Anticoagulants (NOACs).
Aim: To compare the accuracy of DRVV-T with gold standard assays for the assessment of pharmacodynamics of
dabigatran, rivaroxaban and vitamin K antagonist (VKA) in plasma samples from patients.
Methods: Sixty rivaroxaban, 48 dabigatran and 50 VKA samples from patients were included. DRVV-T was
performed in all groups using STA®-Staclot®DRVV-Screen and -Conﬁrm. For NOACs, PT and aPTT were performed
using different reagents while plasma drug concentrations were measured by liquid mass-spectrometry
(LC-MS/MS). For VKA, INR was performed using RecombiPlasTin 2G®.
Results: For NOACs, correlations between calibrated STA®-Staclot®DRVV-Conﬁrm and LC-MS/MS (rs=0.88 and
0.97 for rivaroxaban and dabigatran, respectively) were higher than the ones obtained with STA®-
Staclot®DRVV-Screen (rs = 0.87 and 0.91), PT (rs = 0.83 to 0.86) or aPTT (rs = 0.84 to 0.89). Bland Altman
analyses showed that calibrated DRVV-T methods tend to overestimate plasma concentrations of NOACs. ROC
curves revealed that cut-off to exclude supra-therapeutic levels at Ctrough (i.e. 200 ng/mL) are different for
dabigatran and rivaroxaban. Neither STA®-Staclot®DRVV-Screen nor –Conﬁrm correlated sufﬁciently with the
intensity of VKA therapy (rs = 0.35 and 0.52).
Conclusions: STA®-Staclot®DRVV-Conﬁrm provides a rapid estimation of the intensity of anticoagulation with
rivaroxaban or dabigatran without speciﬁc calibrators. At Ctrough, thresholds for rivaroxaban and dabigatran
can be used to identify supra-therapeutic plasma level. However, this test cannot differentiate the nature of
the NOACs. The development of a point-of-care device optimising this method would be of particular interest
in emergency situations.© 2015 Elsevier Ltd. All rights reserved.Introduction
Non-VKA oral anticoagulations (NOACs) do not require close moni-
toring or frequent dose adjustments as needed for vitamin-K antago-
nists (VKAs). However, searching for the optimal response at the
individual level may still be useful in some situations (e.g. renal or he-
patic impairment; drug-drug interactions, genetic variants) with these
agents [1,2]. In addition, there is a deﬁnite need for knowledge aboutur Thrombosis and Hemostasis
ces (NARILIS), University of
ﬁls).
, Does the Russell Viper Ve
s (2015), http://dx.doi.org/10the intensity of NOAC-induced anticoagulation in acute situations such
as major bleeds or before invasive procedures [3].
Currently, activated partial thromboplastin time (aPTT), Hemoclot
Thrombin Inhibitor® (HTI), ecarin clotting time (ECT) and ecarin
chromogenic assay (ECA) have been proposed for measurements of
dabigatran [4,5] whereas prothrombin time (PT) or anti-Xa chromogenic
assays have been suggested for rivaroxaban [6]. Recent studies concluded
that the aPTT [7] and PT [8] tests do not correlate well with dabigatran
and rivaroxaban concentrations, respectively. Therefore, more speciﬁc
coagulation assays are recommended but these assays are not widely
available and require speciﬁc calibrators and controls that increase the
turnaround time in emergency situations [9]. Consequently, there is a
need for a general test, easily implementable, able to screen the relative
intensity of anticoagulation of all NOACs that could also provide the
nature of the treatment in unconscious patients [10].nom time test provide a rapid estimation of the intensity of oral
.1016/j.thromres.2015.02.020
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ment of antiphospholipid syndrome (APS) [11]. Previous studies sug-
gested that this test could be used for the evaluation of all NOACs but
acknowledged that their preliminary results needed to be validated in
patient samples [12]. Recent ﬁndings conﬁrmed this hypothesis in
plasma samples from patients treated with rivaroxaban [13]. However,
validation with accuratemeasurements of drug levels in plasma and di-
rect comparisons of the effects of dabigatran, rivaroxaban and VKA
treatment on the screening and conﬁrm DRVV-T assay is still lacking.
We hypothesized that DRVV-T could be a useful assay to screen the
relative intensity of dabigatran and rivaroxaban with a sufﬁcient sensi-
tivity and speciﬁcity. The primary objective of this studywas to compare
results obtained with the DRVV-T test to plasma levels of dabigatran
and rivaroxaban measured by validated LC-MS/MS methods. We also
examined if DRVV-T could differentiate between anticoagulant thera-
pies and if thresholds that reﬂect supratherapeutic levels of NOACs in
plasma could be found for the DRVV-T.
Materials and methods
The study was performed in accordance with the Declaration of
Helsinki and was approved by the Medical Ethics Committee of the
Centre Hospitalier Universitaire (CHU) Dinant Godinne UcL Namur in
Yvoir, Belgium, and the Ethical Review Board in Stockholm, Sweden.
Hospitalized patients and ambulatory patients have been recruited at
the CHU Dinant Godinne UcL Namur and at the Karolinska University
Hospital. Written informed consent was obtained from each donor.
Normal pool plasma
Twenty-seven healthy individuals were included. The exclusion
criteria were thrombotic and/or hemorrhagic events, pregnancy, and
use of antiplatelet and/or anticoagulantmedication and/or drugs poten-
tially affecting platelet and/or coagulation factor functions during two
weeks prior to sampling. Blood was taken by antecubital venipuncture
and collected into 0.109 M sodium citrate (9:1 v/v) tubes (Venosafe®,
Terumo, Belgium) using a 21-gauge needle (Terumo, Belgium). Platelet-
poor plasma (PPP) was obtained from the supernatant fraction after dou-
ble centrifugation for 15 minutes at 1500 g at room temperature. Imme-
diately after centrifugation, PPPs from the 27 donors were mixed to
obtain the normal pooled plasma (NPP) which was frozen at −80 °C
without delay. Frozen NPP aliquots were thawed and heated to 37 °C
for 5 minutes just before experiments.
Clinical samples
Sixty rivaroxaban, 48 dabigatran and 50 VKA plasma samples from
real-life patients were included in the study for retrospective analysis.
The majority (n = 47) of VKA samples were from patients treated
with acenocoumarol. There were 3 patients treated with warfarin,
phenprocoumon or ﬂuindione. Exclusion criteria were concomitant
treatment with linezolid (for rivaroxaban samples). To be included in
the study, patientsmust have been on rivaroxaban, dabigatran etexilate
or VKA only, since at least 2 weeks, without any bridgingwith other an-
ticoagulant(s). Patients on rivaroxaban were treated for stroke preven-
tion in non-valvular AF (n = 34; among these, 30 and 4 were treated
with rivaroxaban 20 mg od and 15 mg od, respectively) or for the pre-
vention of recurrent DVT and PE following an acute DVT (n = 26;
among these, 24 were treated with rivaroxaban 20 mg od, one with
15 mg od and one with 15 mg bid, respectively). All patients on
dabigatran etexilate or VKA were treated for stroke prevention in non-
valvular AF. Blood was taken by venipuncture and PPP was obtained
and stored as described above for the healthy volunteers. When sched-
uled, plasma samples from patients treated with NOACs were collected
just before the next pill intake (at Cthrough, i.e. 24 hours for rivaroxaban
od and 12 hours for rivaroxaban and dabigatran etexilate bid) and 2 andPlease cite this article as: Douxﬁls J, et al, Does the Russell Viper Ve
anticoagulation? A cohort study, Thromb Res (2015), http://dx.doi.org/103 hours after the pill intake to achieve measurements at Cmax. For other
samples (n = 12 and 21 for rivaroxaban and dabigatran, respectively),
blood was collected randomly and no information regarding the delay
was available. For VKA samples, blood was taken in a random fashion.Home-made calibrators of rivaroxaban and dabigatran
Powder of rivaroxaban for analyses in Belgium (coagulation assays
and LC-MS/MS measurement) was a generous gift of Bayer A.G.
(Leverkussen, Germany). We used linezolid (Sigma-Aldrich, Diegem,
Belgium) as internal standard due to structural similarities with
rivaroxaban. Rivaroxaban for coagulation analysis was prepared from
a stock solution (1 mg/mL) in 100% DMSO and diluted in PBS without
Ca2+ and Mg2+.
Dabigatran for coagulation testing in Belgium was a generous gift
from Boehringer-Ingelheim GmbH (Ingelheim am Rhein, Germany).
Dabigatran for LC-MS/MS analyses in Stockholm was purchased from
Alsachim (Strasbourg, France) and dabigatran-d3 from Toronto Re-
search Chemicals (Ontario, Canada). Dabigatran for coagulation analysis
was prepared from a stock solution (10 mM) in DMSO plus HCl 5% and
diluted in PBS without Ca2+ and Mg2+.
Working solutions of 1000, 500, 250, 100 and 50 ng/mL of
rivaroxaban and dabigatran were prepared in normal pooled plasma
(NPP). The DMSO concentration in plasma was ≤0.05% (v/v) which
does not inﬂuence the coagulation. “Home-made calibrators” were
always within 20% of the expected values with the LC-MS/MS method.Coagulation assays
Dilute Russell’s Viper Venom time
The commercially available DRVV-T systems include a screening
reagentwith lowphospholipid concentration and a conﬁrmatory product
with high phospholipid concentration.We used the DRVV-T system from
Diagnostica Stago® (STA®-Staclot®DRVV-Screen; NPP baseline clotting
time: 39.8 seconds; standard deviation: 0.4 seconds; and STA®-
Staclot®DRVV-Conﬁrm; NPP baseline clotting time: 35.9 seconds; stan-
dard deviation: 0.3 seconds). The same batchwas used for each reagent.
Brieﬂy, 100 μL of plasma sample was incubated during 240 seconds at
37 °C. Thereafter, 100 μL of STA®-Staclot®DRVV-Screen or -Conﬁrm
was added, starting the reaction on a STA-R Evolution® coagulometer.
Results are given in seconds, as ratios (versus NPP), and, for rivaroxaban
and dabigatran, in ng/mL. For results express in ng/mL, calibration was
performed with homemade calibrators.Prothrombin Time, International Normalized Ratio (INR) and activated
partial thromboplastin time
Prothrombin Time was determined in all patients treated with
rivaroxaban with Triniclot PT Excel S® (TrinityBiotech, Bray,
Ireland; NPP baseline clotting time: 15.6 seconds; standard deviation:
0.2 seconds) and RecombiPlasTin 2G® (Instrumentation Laboratory,
Lexington, USA; NPP baseline clotting time: 10.6 seconds; standard
deviation: 0.1 seconds) while activated partial thromboplastin time
was determined in all patients on dabigatran with STA®C.K. Prest®
(Diagnostica Stago, Asnière, France; NPP baseline clotting time:
30.3 seconds; standard deviation: 0.2 seconds) and SynthasIL® (Instru-
mentation Laboratory; NPP baseline clotting time: 31.4 seconds; stan-
dard deviation: 0.2 seconds). Results are given in seconds, as ratios
(versus NPP), and, for rivaroxaban and dabigatran, in ng/mL. For results
express in ng/mL, calibration was performed with homemade calibra-
tors. For VKA samples, the INR was determined using RecombiPlasTin
2G®. Triniclot PT Excel S®, STA®C.K. Prest® and SynthasIL® were per-
formed on a STA-R Evolution® coagulometer and RecombiPlasTin 2G®
was performed on an ACL-TOP® analyser.nom time test provide a rapid estimation of the intensity of oral
.1016/j.thromres.2015.02.020
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LC-MS/MS measurements were performed in dabigatran and
rivaroxaban samples as previously [7,8]. The detection limits (LOD)
are 1 and 5 ng/mL for dabigatran and rivaroxaban, respectively.
Rivaroxaban
This method has been already described previously and represents
an adaptation of the procedure described by Rohde et al. [14]. Brieﬂy,
sample preparation consisted of mixing 500 μl of methanol containing
the internal standard (linezolid) and 200 μl of plasma sample. The mix
was gently shaken and centrifuged. Separation of the analytes was
achieved on an HPLC Kinetex column (Phenomenex© C18, 2.6 μm,
3.0 mm x 150 mm), using a gradient run with mobile phase A
(10 mM ammonium formate) and mobile phase B (methanol). The
analytes were detected using a Waters© Quattro Micro mass spectrom-
eter operating in positive electrospray ionisation (ESI) mode utilising
multiple reaction monitoring (MRM). No interfering peaks were ob-
served in 15 blank plasmas. The calibration curve for rivaroxaban in
plasma was linear over the range 5–500 ng/ml, and the lower limit of
detection (LLOD) was estimated to 3 ng/ml. Validation experiments
with three levels of control samples (15, 60 and 125 ng/ ml) on three
different occasions (15 determinations per concentration), showed an
inter-assay precision between 5.79 % and 8.11 % and an inter-assay ac-
curacy within the conﬁdence range (±15%). The precision determined
at each concentration level should not exceed 15% of the coefﬁcient of
variation (CV) except for the LLOQ, where it should not exceed 20%
of the CV according to FDA Guidelines for Industry for Bioanalytical
Method Validation [15].
Dabigatran
Thismethod has been already described and represents a simpliﬁca-
tion of the procedure described by Stangier et al. [16]. Brieﬂy, sample
was prepared by protein precipitation of 50 μl citrated plasma with
150 μl acetonitrile containing dabigatran-d3 as an internal standard.
After centrifugation the sample was diluted with an equal amount of
mobile phase A (see below), after which the sample was gently shaken
and re-centrifuged. Separation of the analytes was achieved on an
Acquity UPLC BEH column (Shield RP18, 1.7 μm, 2.1 x 50 mm), using a
gradient run with mobile phase A (10 mM ammonium formate
pH 4.5) and mobile phase B (acetonitrile). The analytes were detected
using a Waters Quattro Premier XE mass spectrometer operating in
positive ESI mode utilising selected reaction monitoring (SRM). No in-
terfering peaks were observed in 18 blank plasmas. The calibration
curve for dabigatran in plasma was linear over the range 1–400 ng/ml
and LLOD was estimated to b0.5 ng/ml. Validation experiments with
three levels of control samples (8.1, 202 and 393ng/ml) on three different
occasions (six determinations per concentration), showed an inter-assay
precision between 6.00% and 9.25% and an inter-assay accuracy between
−0.91% and 3.64%. The precision is reported using the coefﬁcient of
variation and the accuracy is reported as percent recovery by the assay
of known added amount of analyte in the sample according to the
European Medicines Agency guidelines [17].Table 1
Mean plasma drug concentrations according to the delay since the drug administration in patien
expected Cmax of the drugs while 12 hours (dabigatran etexilate) and 24 hours (rivaroxaban) re
sampling have been included (n = 46 and 27 for rivaroxaban and dabigatran etexilate, respec
RIVAROXABAN
2 h
(n = 17)
3 h
(n = 15)
Mean in ng/mL 196 179
Standard Deviation (SD) in ng/mL 110 109
Coefﬁcient Variation (CV) 56% 61%
Min-Max range in ng/mL 17 - 426 35 - 386
Please cite this article as: Douxﬁls J, et al, Does the Russell Viper Ve
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Statistical analyses were performed using GraphPad Prism version
5.00 (GraphPad Software, San Diego California, USA, www.graphpad.
com) and MedCalc (MedCalc Software bvba, Ostend, Belgium, www.
medcalc.org) for Windows. Results for coagulation tests expressed in
ng/mLwere compared to the respective LC-MS/MSmethod by Spearman
correlation analysis and by linear regression. Bland-Altman analyses
were also provided. Sensitivity was deﬁned as the concentration in
rivaroxaban or dabigatran required to double the clotting time of the
NPP. ROC curve analyses were also performed to ﬁnd the best cut-off
to exclude supratherapeutic NOAC concentrations with STA®-
Staclot®DRVV-Screen and –Conﬁrm. The calibration of STA®-
Staclot®DRVV-Screen and –Conﬁrm as well as the correlation between
STA®-Staclot®DRVV assays performed in patients and the true concen-
tration provided by LC-MS/MS analyses is described by a ﬁrst order equa-
tion. The mathematical model is deﬁned as follow: Y = Y0 + (Plateau –
Y0)*(1-e(−K⁎x)) where Y0 is the value when x is zero; plateau is the
Y value at inﬁnite x and K is the rate constant.
The limit of detection (LOD) and the limit of quantitation (LOQ) of
STA®-Staclot®DRVV assays were calculated as follow: LOD= [(3*stan-
dard deviation of Y0)/ slope] and LOQ= [(10*standard deviation of Y0/
slope]. As both STA®-Staclot®DRVV-Screen and –Conﬁrm calibrations
were not deﬁned by a linear correlation on the entire concentration
range (from 0 to 1000 ng/mL), we used the three ﬁrst points of the cal-
ibration curves (0, 50 and 100 ng/mL) to generate a linear response
(R2 b 0.98). The corresponding slope and Y0 were extracted from this
linear model.
Results
Plasma concentrations
Plasma concentrations ranged from 6 to 426 ng/mL for rivaroxaban
and from 0 to 413 ng/mL for dabigatran as determined by LC-MS/MS.
Among the 60 rivaroxaban and the 48 dabigatran samples, 12 (18.6%)
and 6 (12.5%), respectively, were above 200 ng/mL.
Among patients on rivaroxaban and dabigatran etexilate, the interval
between the last intake of the drug and the blood sampling was available
for 60 and 35 samples, respectively (►Table 1).
Among the 50plasma samples of patients treatedwith VKA, the INR-
values ranged from 1.4 to 9.4. Six samples were above an INR of 5.0 and
4 samples were b 2.0.
Correlations between plasma drug concentrations/effects and
STA®-Staclot®DRVV-Screen
Rivaroxaban
The STA®-Staclot®DRVV-Screen yielded a curvilinear concentration-
dependent prolongation of clotting time (►Fig. 1 – rivaroxaban (A)).
The LOD and LOQ were 14 and 46 ng/mL, respectively. The ﬁrst order
equation gave r2-values of 0.82 when results were expressed in seconds
or as ratios (►Fig. 1 – rivaroxaban (A and B)). The Spearman correlation,ts treatedwith rivaroxaban and dabigatran etexilate. Two hours and 3 hours represent the
present the Cmin. Only samples with the exact delay between last administration and drug
tively).
DABIGATRAN ETEXILATE
24 h
(n = 14)
2 h
(n = 8)
3 h
(n = 9)
12 h
(n = 10)
58 168 164 86
68 111 89 37
116% 66% 54% 43%
3 - 245 53 - 386 55 - 363 51 – 172
nom time test provide a rapid estimation of the intensity of oral
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Table 2
Summaryof the Spearman correlation andBland-Altman analyses for the comparison between STA®-Staclot®DRVV-Screen and -Conﬁrm, and (1) calibrated PT (with Triniclot PT Excel S®
and RecombiPlasTin 2G®) and (2) calibrated aPTT (with STA®-C.K.Prest and SynthasIL®) with rivaroxaban and dabigatran plasma concentrations measured by LC-MS/MS, respectively.
STA®-Staclot®DRVV-Screen and –Conﬁrm, PT and aPTT are calibrated with homemade calibrators (see Materials and Methods).
Reference liquid chromatography coupled to tandem mass spectrometry
Spearman Correlation:
rs (95%CI)
Bland-Altman analyses: mean
difference (95% limit of
agreement) in ng/mL
Slope of the linear
regression (95% CI)
Intercept (95% CI)
RIVAROXABAN
Calibrated† STA®-Staclot® DRVV-Screen 0.89 (0.82-0.93) −21 (−132 to 90) 0.9592 (0.8186 – 1.100) 25.76 (3.28 – 48.24)
Calibrated† STA®-Staclot® DRVV-Conﬁrm 0.89 (0.82-0.94) −16 (−118 to 87) 0.8764 (0.7499 – 1.003) 30.72 (10.48 – 50.95)
Calibrated† Triniclot PT Excel S® 0.84 (0.75-0.91) 16 (−134 to 166) 0.7026 (0.5280 – 0.8771) 20.03 (−7.89 – 47.95)
Calibrated† HemosIL RecombiPlasTin 2G® 0.89 (0.82-0.93) −66 (−179 to 48) 1.018 (0.8731 – 1.162) 63.64 (40.51 – 86.76)
DABIGATRAN
Calibrated† STA®-Staclot® DRVV-Screen 0.84 (0.72-0.91) −37 (−173 to 99) 1.283 (1.096 – 1.470) 5.68 (−22.12 – 33.48)
Calibrated† STA®-Staclot® DRVV-Conﬁrm 0.94 (0.89-0.97) −40 (−155 to 74) 1.343 (1.203 – 1.482) 2.66 (−18.07 – 23.39)
Calibrated† STA®-C.K.Prest 0.79 (0.64-0.88) −25 (−219 to 169) 1.612 (1.383 – 1.842) −42.62 (−76.67 – -8.56)
Calibrated† HemosIL SynthasIL® 0.82 (0.69-0.90) −32 (−231 to 168) 1.614 (1.374 – 1.854) −36.06 (−71.67 – -0.45)
† All analyses are provided for results expressed in ng/mL.
5J. Douxﬁls et al. / Thrombosis Research xxx (2015) xxx–xxxthe linear regression and the Bland-Altman analyses for results expressed
in ng/mL are provided in ►Fig. 1 – rivaroxaban (C & D) and in ►Table 2.
Dabigatran
The STA®-Staclot®DRVV-Screen yielded a concentration-dependent
prolongation of clotting time (►Fig. 1 – dabigatran (A)). The LOD and
LOQ were 6 and 20 ng/mL, respectively. The ﬁrst order equation gave
r2-values of 0.77 and 0.78 when results were expressed in seconds or
as ratios, respectively (►Fig. 1 – dabigatran (A and B)). The Spearman
correlation, the linear regression and the Bland-Altman analyses for re-
sults expressed in ng/mL are provided in ►Fig. 1 – dabigatran (C & D)
and in ►Table 2.
Vitamin K antagonists
The STA®-Staclot®DRVV-Screen reﬂected the prolongation of clotting
time poorly (►Supplementary Material – Fig. 1). The Spearman correla-
tion coefﬁcients between INR-values and STA®-Staclot®DRVV-Screen in
seconds or ratio were 0.35 (95% CI: 0.07 – 0.58; p = 0.0139; r2 for the
linear regression 0.20) and 0.35 (95% CI: 0.07 – 0.58; p = 0.0128; r2 for
the linear regression 0.20), respectively.
Correlations between plasma drug concentrations/effects and
STA®-Staclot®DRVV-Conﬁrm
Rivaroxaban
The STA®-Staclot®DRVV-Conﬁrmyielded a concentration-dependent
prolongation of clotting time (►Fig. 2 – rivaroxaban). The LOD and LOQ
were 12 and 40 ng/mL, respectively. The ﬁrst order equation gave
r2-values of 0.84whether the results were expressed in seconds or as ra-
tios (►Fig. 2 – rivaroxaban (A andB)). The Spearman correlation, the lin-
ear regression and the Bland-Altman analyses for results expressed in
ng/mL are provided in ►Fig. 2 – rivaroxaban (C & D) and in ►Table 2.
Dabigatran
The STA®-Staclot®DRVV-Conﬁrmyielded a concentration-dependent
prolongation of clotting time (►Fig. 2 – dabigatran (A)). The LOD and
LOQ were 5 and 16 ng/mL, respectively. The ﬁrst order equation gave
r2-values of 0.91 whether results were expressed in seconds or as ratiosFig. 1. Correlation between STA®-Staclot®DRVV-Screen and LC-MS/MS. Results for rivaroxaban
B and 1C show results expressed in seconds, as ratio and in ng/mL, respectively. Fig. 1D present
calculated as follow: [difference (A-B) vs. average]where A is the result of LC-MS/MS andB the r
a ratio of 2.7 could exclude plasma drug concentration above 200 ng/mL, as provided by the R
provided by the ROC analysis.
Please cite this article as: Douxﬁls J, et al, Does the Russell Viper Ve
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gression and the Bland-Altman analyses for results expressed in ng/mL
are provided in ►Fig. 2 – dabigatran (C & D) and in ►Table 2.
Vitamin K antagonists
The STA®-Staclot®DRVV-Conﬁrm poorly reﬂected the prolongation
of clotting time (►Supplementary Material – Fig. 1). The Spearman
correlation coefﬁcients between INR-values and STA®-Staclot®DRVV-
Conﬁrm in seconds or ratio were 0.51 (95% CI: 0.27 – 0.70; p =
0.0001; r2 for the linear regression 0.28) and 0.52 (95% CI: 0.27 – 0.70;
p = 0.0001; r2 for the linear regression 0.28), respectively.
ROC curve analyses
ROC curves analyses yielded different cut-offs for the threshold at
200 ng/mL. Sensitivities, speciﬁcities, positive and negative likelihood
ratios, and positive and negative predictive values are summarised in
►Table 3. ROC curves are provided in ►Supplementary Material - Fig. 2.
Correlations between plasma drug concentrations and PT or aPTT
►Table 2 mentions Spearman correlations, Bland-Altman analyses
and the slopes of the linear regressions performed for rivaroxaban and
dabigatran samples with calibrated PT and aPTT. ►Supplementary
Material - Figs. 3 and 4 show results for the linear correlations between
PT (rivaroxaban) and aPTT (dabigatran), plasma concentrations mea-
sured by LC-MS/MS and the corresponding Bland-Altman analyses.
Clinical outcomes
This study was not intended to investigate the efﬁcacy and safety of
rivaroxaban, dabigatran etexilate andVKAs. However, clinical datawere
obtained from patients in this cohort (►Table 4). This includes recur-
rence of thrombus in the right atrium (n= 1: dabigatran etexilate), su-
perﬁcial venous thrombosis (SVT) (n = 1: rivaroxaban and n = 2:
dabigatran etexilate), recurrence of stroke (n = 2: rivaroxaban and
n = 1: VKA) or pulmonary embolism (n = 1: rivaroxaban and n = 3:
VKA), embolism (n= 1: VKA), hematoma (n= 1: dabigatran etexilate
and n = 2: VKA), gynaecological bleedings (n = 3: rivaroxaban) andand dabigatran are presented on the left and on the right of theﬁgure, respectively. Fig. 1A,
s the results of the Bland-Altman analysis. For the Bland Altman analysis, the difference is
esult of STA®-Staclot®DRVV-Screen. For rivaroxaban results below107.7 seconds or below
OC analysis. For dabigatran, the same cut-off results in 139.9 seconds and a ratio of 3.5, as
nom time test provide a rapid estimation of the intensity of oral
.1016/j.thromres.2015.02.020
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by LC-MS/MS at the different blood sampling times (for rivaroxaban
and dabigatran), the INR (for VKA) and the results of the STA®-
Staclot®DRVV-Conﬁrm expressed in ratio (for rivaroxaban, dabigatran
etexilate andVKA) for these outcomes are detailed in►Table 4. All anal-
yses were performed after the clinical outcome occurred.
Discussion
Both STA®-Staclot®DRVV-Screen and -Conﬁrm correlatedwell with
dabigatran and rivaroxaban plasma concentrations (►Table 2). STA®-
Staclot®DRVV-Conﬁrm always provides better r2-values than did PT
and aPTT for rivaroxaban anddabigatran samples (►Table 2). In addition,
the present results conﬁrm previous observations of inter-reagent vari-
ability not only in terms of sensitivity but also regarding the inter-
individual response when testing for PT with rivaroxaban (►Table 2).
STA®-Staclot®DRVV-Screen and -Conﬁrm showed higher LOD and
LOQ than the Biophen DiXaI® for rivaroxaban and lower LOD and LOQ
values than the ones obtained previously with the Hemoclot Thrombin
Inhibitor® (HTI) for dabigatran [7,8].
In terms of sensitivity, STA®-Staclot®DRVV-Screen performed
better than PT and aPTT. The sensitivity of STA®-Staclot®DRVV-Conﬁrm
was higher than the one of aPTT for dabigatran, while for rivaroxaban,
depending on the PT reagent; the sensitivity was either similar (Triniclot
PT Excel S®) or better (RecombiPlasTin 2G®).
Bland-Altman analyses show that STA®-Staclot®DRVV-Screen and
-Conﬁrm also perform slightly better than PT and aPTT, mainly due to
closer 5th-95th limits of agreement (►Table 2). However, the mean de-
viation from the reference measurement is large (i.e. 40 ng/mL, which
represents a mean deviation of ±30 % compared to the mean concen-
tration of all dabigatran samples) for both DRVV-T assays. This pre-
cludes their recommendation for the accurate estimation of plasma
drug concentrations. Nevertheless, the present LC-MS/MS assay for
dabigatran measured free (unconjugated) dabigatran, which is ±20%
lower than the total concentration in plasma [16,18]. This can contribute
but does not explain entirely the discrepancy for dabigatran plasma
concentrations measured by this technique and the estimations of
DRVV-T assays. Moreover, the different cut-offs mention in the regula-
tory documents are established with the dTT (i.e. HTI) [19] andwe pre-
viously found that the LC-MS/MS method used in this study correlates
very well with this test [7]. An adapted methodology of this test even
allowed an accurate assessment of plasma concentrations b50 ng/mL
[20].
A limitation of our study is thatwe only tested STA®-Staclot®DRVV-
Conﬁrm on a STA-R Evolution® coagulometer. However, compared to
routine coagulation assays, i.e. PT or aPTT, DRVV-T should be less affect-
ed by inter-reagent variability since there are fewer sources of Russell’s
venom compared to the sources of thromboplastins (for PT) and activa-
tors of the contact pathway (for aPTT). However, the composition of
phospholipids may differ between the different DRVVT reagents com-
mercially available and could affect the sensitivity towards dabigatran
and rivaroxaban [12]. Furthermore, the availability of DRVVT is not
guaranteed in any laboratories 24/7 and its cost may also be a limitation
since to date, the majority of DRVVT reagents are not liquid stable. This
latter concern could lead to a waste of reagent, an increased turn-
around time and ﬁnally a more expensive analysis.
The current Pradaxa® EU-SmPC states that it can be assumed that
measures of anti-coagulant activity reﬂect dabigatran levels and can
provide guidance for the assessment of bleeding risk, and that exceed-
ing the 90th percentile of dabigatran trough levels (i.e. 200 ng/mL inFig. 2. Correlation between STA®-Staclot®DRVV-Conﬁrm and LC-MS/MS. Results for rivaroxa
Fig. 2A, B and 2C show results expressed in seconds, as ratio and in ng/mL, respectively. Fig. 2D
ference is calculated as follow: [difference (A-B) vs. average] where A is the result of LC-M
69.7 seconds or below a ratio of 1.9 could exclude plasma drug concentration above 200
98.8 seconds and a ratio of 2.7, as provided by the ROC analysis.
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anticoagulation? A cohort study, Thromb Res (2015), http://dx.doi.org/10NVAF) is associated with an increased risk of bleeding [19]. This is in
line with a recent investigation made by the BMJ revealing that if the
plasma levels of dabigatran were measured and the dose was adjusted
accordingly, major bleeds could be reduced by 30-40% compared with
well controlled warfarin [21]. The French group “Groupe d’Intérêt en
Hémostase Périopératoire (GIHP)” proposed a similar approach for
rivaroxaban than the one stated for dabigatran and mention a cut-off
at 200 ng/mL at Ctrough (i.e. 24 hours after the previous dose) as associ-
ated with an increased bleeding risk [22]. Therefore, a global test, easily
implementable and widely performed, able to identify the anticoagulant
and to screen the relative intensity of anticoagulation of all NOACs in
urgent settings, is required [10].
Previous studies stated that the DRVV-T is inﬂuenced by
rivaroxaban [13,23,24] and that it could be useful to assess pharmaco-
dynamics of NOACs [12,13,25]. This test might therefore be used for
testing a wide range of NOACs rather than using different tests for
each agent [12].
Is the Dilute Russell Viper Venom Time a useful test to complement routine
coagulation assays facing a bleeding emergency?
Based on the present results we recommend the use of STA®-
Staclot®DRVV-Conﬁrm which assessed the relative intensity of
anticoagulation due to rivaroxaban and dabigatran more accurately
than PT or aPTT. STA®-Staclot®DRVV-Screen and –Conﬁrm showed sim-
ilar properties regarding the Spearman correlation, the Bland-Altman
analysis or the LOD and LOQ while STA®-Staclot®DRVV-Screen was a
bit more sensitive. On the other hand, due to a high level of phospho-
lipids, STA®-Staclot®DRVV-Conﬁrm is less inﬂuenced by APS antibodies.
This is the main reason why STA®-Staclot®DRVV-Conﬁrm should be
preferred to the screening test but this also results into the decreased
sensitivity towards rivaroxaban and dabigatran (►Figs. 1 & 2).
At the threshold concentration of 200 ng/mL, data obtained are
signiﬁcantly different for rivaroxaban and dabigatran either with
STA®-Staclot®DRVV-Screen or –Conﬁrm (►Table 3). As a consequence,
no single speciﬁc cut-off for both agents can be proposed and thus,
different interpretations are needed for rivaroxaban and dabigatran
treated patients. Importantly, it is preferable to express the results in
ratio since it reduces the inter-lot variability.
The main advantage of STA®-Staclot®DRVV-Conﬁrm is that it
provides rapid estimation of the intensity of anticoagulation without
requiring speciﬁc calibrants like more speciﬁc coagulation assays.
More explicitly, at Ctrough, above-mentioned thresholds (►Table 3) for
rivaroxaban and dabigatran can be used to identify supra-therapeutic
plasma levels while the results of the thrombin time (TT), PT and aPTT
may help to differentiate between therapies [10]. Concerning the VKA-
treated patients, both STA®-Staclot®DRVV-Screen and –Conﬁrm did
not correlate with INR. One possible hypothesis is that, as DRVV-T is
not sensitive towards factor VII while the INR well, it is possible that a
part of the variability is due to this difference in the principle of the
tests. This has also been underlined with the Fiix-PT, a modiﬁed PT
which is sensitive only to reduction of FII and FX [26]. The authors of
this previous study found that while the The Fiix-PT (Fiix-INR) correlat-
ed well with PT (INR), it ﬂuctuated less than the INR in anticoagulated
patients reﬂecting its insensitivity to FVII.
Clinical outcomes
For rivaroxaban, 2 recurrences of stroke were associated with plasma
concentrations below the 5th percentile observed in AF population atban and dabigatran are presented on the left and on the right of the ﬁgure, respectively.
presents the results of the Bland-Altman analysis. For the Bland Altman analysis, the dif-
S/MS and B the result of STA®-Staclot®DRVV-Conﬁrm. For rivaroxaban results below
ng/mL, as provided by the ROC analysis. For dabigatran, the same cut-off results in
nom time test provide a rapid estimation of the intensity of oral
.1016/j.thromres.2015.02.020
Table 3
Summary table of ROC Curves analysis for STA®-Staclot®DRVV-Screen and -Conﬁrm. For the deﬁned cut-offs (in seconds and in ratio), the sensitivity (95% conﬁdence interval (CI)), spec-
iﬁcity (95% conﬁdence interval), positive (+) likelihood ratio, negative (−) likelihood ratio, positive predictive value and negative predictive value were calculated.
Cut-off Sensitivity (95% CI) Speciﬁcity (95% CI) + predictive
value
- predictive
value
seconds ratio
STA®-Staclot® DRVV-Screen
rivaroxaban 107.7 2.7 100.0 (100.0 - 100.0) 66.7 (51.6 - 79.6) 40.7 100.0
dabigatran 139.9 3.5 100.0 (100.0 - 100.0) 92.9 (80.5 - 98.4) 66.7 100.0
STA®-Staclot® DRVV-Conﬁrm
rivaroxaban 69.7 1.9 100.0 (100.0 - 100.0) 70.8 (55.9 - 83.0) 60.6 100.0
dabigatran 98.8 2.7 100.0 (100.0 - 100.0) 100.0 (100.0 - 100.0) 100.0 100.0
8 J. Douxﬁls et al. / Thrombosis Research xxx (2015) xxx–xxxCtrough (i.e. 12 ng/mL) [27]; one pulmonary embolism was associated
with a plasma level at Cmax below the 5th percentile of the population
studied in DVT treatment (i.e. 189 ng/mL) and one gingival bleeding
was seen in a patient with a plasma drug concentration above the 95th
percentile of the ROCKET-AF study (i.e. 137 ng/mL) [27]. For the 3
gynaecological bleedings and the SVT, rivaroxabanplasma concentrations
were within the 5th – 95th percentile range for both Ctrough and Cmax.
Among patients on dabigatran etexilate, one SVT and one recurrence of
thrombus in the right atrium were associated with a concentration
below the 25th percentile of plasma concentrations observed in RE-LYTable 4
Plasma concentrations (for rivaroxaban and dabigatran), INR (for VKA) and DRVV-T results of
with LC-MS/MS. For rivaroxaban, blood was taken 2, 3 (Cmax) and 24 (Ctrough) hours after the l
hours after the last drug intake. For VKA therapy, blood was taken randomly. All analyses were
Delay since the drug inta
RIVAROXABAN
2 hours
Clinical event (n = 7) ng/mL DRVV-
Pulmonary embolism NA
Recurrence of stroke (1) 183 2.0
Recurrence of stroke (2) NA
Superﬁcial venous thrombosis and gingival bleeding‡ NA
Gynaecological bleeding 247 2.0
Gynaecological bleeding NA
Gynaecological bleeding 238 2.1
DABIGATRAN ETEXILATE
2 hours
Clinical event (n = 4) ng/mL DRVV-
Recurrence of thrombus in the right atrium 107 2.3
Superﬁcial venous thrombosis (1) 143 2.5
Superﬁcial venous thrombosis (2) 386 3.3
Hematoma 152 2.1
VITAMIN K ANTAGONIST
Clinical event (n = 7) INR
Pulmonary embolism
2.5
Pulmonary embolism
2.2
Pulmonary embolism
1.9
Recurrence of stroke
1.4
Hematoma
4.9
Hematoma
5.4
Embolism⁎
2.0
NA: Not available
† DRVV-T: results are those obtained with STA®-Staclot®DRVV-Conﬁrm expressed in ratio.
‡ The same patient complained a superﬁcial venous thrombosis and a gingival bleeding at th
⁎ Localisation not speciﬁed
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anticoagulation? A cohort study, Thromb Res (2015), http://dx.doi.org/10at Ctrough (i.e. 61 ng/mL) and at Cmax (i.e. 117 ng/mL), respectively [19].
The other outcomeswere not associatedwith plasma concentrations out-
side concentration ranges obtained in large phase-III trials. Several case
reports showed an association between extreme plasma drug concentra-
tions and efﬁcacy/safety outcomes [28,29] but large cohort studies are
required to conﬁrm this hypothesis. For VKA treated patients, failure of
treatment occurred in 3 patients within the therapeutic range while
one recurrence of strokewas observed in onepatientwith subtherapeutic
INR. Supratherapeutic INR was observed in 2 patients experiencing
massive hematoma.patients experiencing clinical events in this study. Plasma concentrations were measured
ast drug intake while for dabigatran etexilate, blood was taken 2, 3 (Cmax) and 12 (Ctrough)
performed after the clinical outcomes occurred.
ke
3 hours 24 hours (+/−1 hour)
T† ng/mL DRVV-T ng/mL DRVV-T
47 1.6 13 1.0
192 2.0 8 1.1
213 1.9 3 1.0
NA 245 2.0
206 2.1 8 1.00
35 1.6 NA
NA 121 1.7
3 hours 12 hours (+/−1 hour)
T ng/mL DRVV-T ng/mL DRVV-T
136 2.2 75 1.8
154 2.4 51 1.7
363 3.4 172 2.6
NA 106 1.9
S
DRVV-T
1.3
1.1
1.1
1.0
2.1
2.9
1.6
e consultation.
nom time test provide a rapid estimation of the intensity of oral
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Our proposed thresholds for STA®-Staclot®DRVV-Conﬁrm should
be conﬁrmed in large, preferably multicentric prospective studies com-
paring different DRVVT kits with clinical outcomes. These preliminary
results should also serve as hypotheses to develop a point-of-care
device that would be of particular interest in emergency situations.
Conclusions
STA®-Staclot®DRVV-Conﬁrm may provide clinicians and biologists
with rapid information on the intensity of anticoagulation with NOACs.
However, it cannot directly inform the physician on the nature of the
drug but the use of TT, alone or complement with PT and aPTT, may
help in differencing therapies. DRVV-T using the conﬁrm reagent is
more informative than PT and aPTT to identify supra-therapeutic levels
of rivaroxaban and dabigatran at Ctrough. These results also provide an
interesting perspective for the development of a DRVV-T point-of-care
device implementable in emergency units.
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